NOVOMIX 30 30 UNIT
INSULIN ASPART : 30 UNIT INSULIN ASPART PROTAMINE : 70 UNIT · DIN 02265435 · NOVO NORDISK CANADA INC
Health Canada status: MARKETED
What is NOVOMIX 30?
NOVOMIX 30 30 UNIT contains INSULIN ASPART : 30 UNIT INSULIN ASPART PROTAMINE : 70 UNIT. It is listed in the Health Canada Drug Product Database under DIN 02265435, held by NOVO NORDISK CANADA INC, supplied as SUSPENSION for SUBCUTANEOUS administration. Health Canada currently lists it as marketed, status dated 12-Sep-2005. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is NOVOMIX 30 used for?
Treatment of adult patients with diabetes mellitus who require insulin for the control of hyperglycemia.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02265435 |
|---|---|
| Brand name | NOVOMIX 30 |
| Generic / active ingredient | INSULIN ASPART : 30 UNIT INSULIN ASPART PROTAMINE : 70 UNIT |
| Manufacturer | NOVO NORDISK CANADA INC |
| Strength | 30 UNIT |
| Dosage form | SUSPENSION |
| Route of administration | SUBCUTANEOUS |
| Schedule | Schedule D |
| ATC code | A10AD05 INSULIN ASPART |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 12-Sep-2005 |
How is it administered?
Subcutaneous injection immediately before (within 5-10 min) or after a meal. Individualized dosage, usually 0.5-1.0 units/kg/day. Rotate injection sites.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text snippet (standard insulin storage usually applies, but text cuts off before section 11 details).
How is it supplied?
3 mL Penfill cartridges, package size of 5 x 3 mL.
Contraindications
During episodes of hypoglycemia; hypersensitivity to the drug or any ingredient in the formulation.
Warnings and precautions
Hypoglycemia risk; do not administer IV or in infusion pumps; resuspend properly before use; risk of medication errors/mix-ups; potential for hypokalemia.
What can be used instead?
Other Canadian products sharing ATC code A10AD05 INSULIN ASPART. 1 of 2 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| NOVOMIX 30 (FLEXPEN) | 30 % | SUSPENSION | NOVO NORDISK CANADA INC | CANCELLED PRE MARKET | DIN 02265443 |
Who else supplies INSULIN ASPART worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. INSULIN ASPART appears in 441 registered pack listings across 11 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.